Exploring the Tools in Nanoparticle Analysis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Exploring the Tools in Nanoparticle Analysis
Nanotechnology is an important area of drug and biomedical research, and advancing nano-analysis is crucial for its further development.


Pharmaceutical Technology
Volume 34, Issue 7, pp. 44-46

Enhanced technology

Surface-enhanced Raman spectroscopy (SERS). Raman methods are also useful in evaluating metallic nanoparticles, which can be used in nanomedicines, diagnostics, or biomedical imaging. Scientists at the National Institute of Standards and Technology (NIST) recently used surface-enhanced Raman spectroscopy (SERS) to test the properties of nanostars or star-shaped gold nanoparticles. They found that the nanostars had better optical qualities than other nanospheres commonly used for Raman enhancement, thereby making them for a range of applications, including disease diagnostics. (3).

SERS relies on metallic nanoparticles, most commonly gold and silver, to amplify signals from molecules present in only trace quantities. The NIST researchers tested the optical properties of the nanostars using two target molecules: 2-mercaptopyridine and crystal violet, which were selected because of their structural similarity to biological molecules and their large number of delocalized electrons, a characteristic that lends itself to SERS, according to NIST. The researchers found that the Raman signal of 2-mercaptopyridine was 100,000 times stronger when nanostars were present in the solution. The nanostars also enhanced the signature of crystal violet and delivered a signal about 10 times stronger than nanorods, another type of nanosphere.

Shell-isolated nanoparticle-enhanced Raman spectroscopy (SHINERS). Researchers at the Georgia Institute of Technology in Atlanta and Xiamen University in Xiamen, China, recently reported on what they have classified as shell-isolated nanoparticle-enhanced Raman spectroscopy (SHINERS), a method which they believe could be developed into a nondestructive and flexible portable characterization tool for drug and food inspections as well as for characterizing living cells through in-situ detection of cell-wall proteins (4).

Their research addressed the limitations of SERS by obtaining high quality Raman spectra of various molecules adsorbed at platinum and silver single-crystal surfaces with different facets in an electrochemical environment. In SHINERS, the Raman signal is amplified by gold nanoparticles with an ultrathin silica or alumina shell. A monolayer of these nanoparticles, or so-called "smart dust," is spread over the surface to be probed. The ultrathin coating prevents the nanoparticules from agglomerating, protects the SERS-active nanostructure from contact with the probed material, and allows the "smart dust" to conform to different contours and morphologies of a given substrate. The researchers used a three-dimensional finite-difference time-domain method to simulate the related enhancement. The results showed that SHINERS can be applied in probing surface composition, adsorption, and processes of diverse objects and morphologies. It may also be applied to general spectroscopy such as IR spectroscopy, sum frequency generation, and fluorescence.

Other methods. The NIST and the National Cancer Institute's Nanotechnology Characterization Laboratory (NCL) are engaged in ongoing research in the characterization of nanomaterial formulations for cancer treatments. Some examples of their work include isotope dilution mass spectrometric analysis of a nanoemulsion submitted by NCL for gadolinium content; the development of a method based on size-exclusion chromatography with inductively coupled plasma–mass spectrometry detection to quantitatively distinguish between free and complexed forms of gadolinium; and analysis of tissue samples for toxicological study of gold nanoparticles.

References

1. S. Webster and K.J Baldwin, Pharm. Technol. Europe, http://pharmtech.findpharma.com/pharmtech/Analytical/Raman-as-a-PAT-Tool/ArticleStandard/Article/detail/173525/, accessed June 21, 2010.

2. R.L. Green and C.D Brown, Pharm. Technol. 33 (10), 72–82 (2008).

3. E. Nalbant Esenturk and A.R. Hight Walker, J. Raman Spec. 40 (1), 86–91 (2008).

4. J. Feng et al., Nature 426 (7287), 392–395 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here